Document Detail

Tyrosine kinase inhibitors to treat liver cancer.
MedLine Citation:
PMID:  20128706     Owner:  NLM     Status:  MEDLINE    
IMPORTANCE OF THE FIELD: Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide. Although patients with early-stage disease have a good prognosis, there has been no effective therapy available for those with advanced disease. Despite the death risk of patients with advanced HCC being reduced with sorafenib therapy, many patients eventually turn out to be refractory to this therapy. Thus, treatment of HCC remains an urgent health concern. AREAS COVERED IN THIS REVIEW: Recent improvement in understanding the pathophysiology of HCC at the molecular level has fostered the development of molecular targeted therapies that specifically block the disrupted pathways. WHAT THE READER WILL GAIN: This review summarizes the preclinical and clinical data from 2004 to 2009 on the efficacy and safety of the emerging drug for the treatment of HCC, including small molecule inhibitors (erlotinib, sunitinib, sorafenib, vandetanib, cediranib, brivanib and dovitinib) and the rationale for combination therapies for patients with advanced HCC. TAKE HOME MESSAGE: Understanding the mechanisms of action, safety and efficacy of these new agents and new methods of combining these drugs may help prolong overall survival of patients with HCC and reduce disease recurrence after surgery or ablative therapies.
Hung Huynh
Related Documents :
18796686 - Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with tra...
17868066 - Liver transplantation for hepatocellular carcinoma: validation of the ucsf-expanded cri...
20380016 - Surgical spacer placement and proton radiotherapy for unresectable hepatocellular carci...
3263266 - Endoscopic sclerotherapy of bleeding esophageal varices. a comparative study of results...
20800716 - The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer.
16189146 - The influence of extent of surgical margin positivity on prostate specific antigen recu...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert opinion on emerging drugs     Volume:  15     ISSN:  1744-7623     ISO Abbreviation:  Expert Opin Emerg Drugs     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-08     Completed Date:  2010-06-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101135662     Medline TA:  Expert Opin Emerg Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  13-26     Citation Subset:  IM    
National Cancer Centre of Singapore, Humphrey Oei Institute of Cancer Research, Division of Cellular and Molecular Research, Laboratory of Molecular Endocrinology, 11 Hospital Drive, 169610, Singapore.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Hepatocellular / drug therapy*,  epidemiology
Drug Delivery Systems / methods*
Drugs, Investigational / therapeutic use*
Liver Neoplasms / drug therapy*,  epidemiology
Protein Kinase Inhibitors / pharmacology,  therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Signal Transduction / drug effects
Reg. No./Substance:
0/Drugs, Investigational; 0/Protein Kinase Inhibitors; EC Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  In-flight automated external defibrillator use and consultation patterns.
Next Document:  RNA as performance-enhancers for dendritic cells.